EHA 2023 | Real-world study evaluating the outcomes of patients with R/R ALL receiving HSCT
Alexander Russell-Smith, BA, MSc, Pfizer, London, UK, shares the findings from a real-world study evaluating the outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who have received hematopoietic stem cell transplantation (HSCT). Mr. Russel-Smith comments on the challenges associated with conducting such studies and explains that recent transplant practices have improved survival following HSCT. In addition, factors including pre-transplant measurable residual disease (MRD) negativity were associated with higher survival probability. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer: employee and stock ownership
